Chemours (CC) said Wednesday that it now expects fiscal Q2 net sales to reach the high end of its previously announced forecast of a low to mid-teens sequential increase.
Analysts polled by FactSet expect a fiscal Q2 net sales of $1.56 billion.
The company also said it now expects fiscal Q2 adjusted EBITDA of $215 million to $225 million as adjusted EBITDA from its Titanium Technologies segment is estimated to decline by about 15% sequentially due to operational disruptions at certain US sites.
Chemours previously estimated a 40% to 45% increase in fiscal Q2 adjusted EBITDA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.